Dianthus Therapeutics, Inc. /DE/ (DNTH) Financial Statements
Dianthus Therapeutics, Inc. /DE/ (DNTH) files with the U.S. Securities and Exchange Commission under CIK 0001690585. 10KGenie shows its annual and quarterly statements from SEC filings.
Key Figures, Fiscal Year 2025
- Revenue
- $2.04 million
- Net Income
- -$162.34 million
- Total Assets
- $530.92 million
- Net Cash from Operations
- -$129.06 million
Fiscal year ended Dec 31, 2025. Latest periodic SEC filing: Aug 4, 2026. Source: SEC filings (EDGAR XBRL).
Open the full financial statements for DNTH in 10KGenie
Data from SEC EDGAR filings. 10KGenie is not affiliated with the SEC. SEC Filing History